Danaher Co. (NYSE:DHR) Shares Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC raised its stake in Danaher Co. (NYSE:DHR) by 5.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,426 shares of the conglomerate’s stock after buying an additional 555 shares during the quarter. Summit Trail Advisors LLC’s holdings in Danaher were worth $3,180,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Legal & General Group Plc grew its holdings in Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after buying an additional 139,989 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Danaher by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after buying an additional 85,081 shares in the last quarter. Swedbank AB purchased a new stake in Danaher in the 1st quarter valued at $676,545,000. Finally, Blair William & Co. IL grew its holdings in Danaher by 0.9% in the 2nd quarter. Blair William & Co. IL now owns 1,777,030 shares of the conglomerate’s stock valued at $443,991,000 after buying an additional 15,766 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

DHR stock opened at $235.84 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $170.34 billion, a P/E ratio of 45.01, a P/E/G ratio of 4.32 and a beta of 0.85. The business’s 50-day moving average is $258.15 and its two-hundred day moving average is $259.95. Danaher Co. has a 1 year low of $215.68 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 EPS. Analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DHR. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Royal Bank of Canada lowered their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, KeyCorp increased their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $287.16.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.